OCCL (OCCLLTD)

FairStock Score: 60/100 — STEADY

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 11.40 and P/B of 1.32 provide a modest valuation relative to book value of ₹76.32
• Piotroski F-Score of 7/9 points to reasonable financial health
• Profit growth of 69.71% with sales growth of 18.69% shows strong recent momentum
• PEG of 0.26 suggests the market is pricing in much lower growth than recent performance
• Promoter holding of 51.76% aligns owner interests

Concerns

• Commodity chemicals business may lack durable pricing power and is vulnerable to cyclical swings
• Latest quarter net profit of ₹7 Cr on sales of ₹114 Cr implies a thin net margin
• ROE of 9.69% is below what I would expect from a wide-moat franchise
• Debt-to-equity is not disclosed, so leverage risk cannot be fully assessed

AI Analysis

Let me start with what I like. At ₹101.01, OCCL is available at a P/E of 11.40 and a P/B of 1.32. That is not an expensive price for a business producing a 14.90% ROCE and a 9.69% ROE. The promoter holding of 51.76% is comfortable, and a Piotroski F-Score of 7 out of 9 suggests the financial position is reasonably sound. Dividend yield of 1.67% gives me a small return while I wait. The reported profit growth of 69.71% on sales growth of 18.69% looks eye-catching, and the PEG of 0.26 makes the growth seem very cheap. But I have to be careful. OCCL is a commodity chemicals company. That means pricing power may be limited, and earnings can swing with supply, demand, and input costs. The latest quarter tells me to stay grounded: sales of ₹114 Cr produced only ₹7 Cr of net profit, a thin net margin. If that margin is the new normal, today's low P/E is not as compelling as it first appears. Also, ROE below 10% is acceptable but not the hallmark of a wonderful franchise. The stock has fallen from ₹184.50 to ₹101.01, so Mr. Market has already soured on it. Something may be wrong, or sentiment may be excessive. The data does not disclose debt-to-equity, and the FairStock score is insufficient, so I cannot fully verify financial health. I would want to know more about the balance sheet, capacity utilization, and competitive position before investing. At the right price, a cyclical can be a fine investment, but I need a real margin of safety, not just a low P/E.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer